Commerzbank Aktiengesellschaft FI Purchases Shares of 12,471 Gilead Sciences, Inc. $GILD

Commerzbank Aktiengesellschaft FI acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 12,471 shares of the biopharmaceutical company’s stock, valued at approximately $1,385,000.

A number of other hedge funds also recently modified their holdings of the stock. Rothschild Investment LLC raised its holdings in Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 84 shares during the period. Hemington Wealth Management grew its position in shares of Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 85 shares during the last quarter. Ignite Planners LLC increased its stake in shares of Gilead Sciences by 1.1% during the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares during the period. Archer Investment Corp increased its stake in shares of Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in Gilead Sciences by 0.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock worth $3,912,000 after purchasing an additional 87 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $135.93 on Monday. The company’s 50-day moving average price is $123.98 and its two-hundred day moving average price is $118.71. The firm has a market cap of $168.65 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12 month low of $92.26 and a 12 month high of $136.30.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter last year, the business posted $2.02 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insiders Place Their Bets

In related news, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the sale, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. The trade was a 67.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the insider directly owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 141,757 shares of company stock valued at $17,569,112 over the last ninety days. 0.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on GILD shares. BMO Capital Markets reiterated an “outperform” rating on shares of Gilead Sciences in a research report on Tuesday, January 13th. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Sanford C. Bernstein set a $135.00 price objective on shares of Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday. Finally, Citigroup raised their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $133.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.